Literature DB >> 13835653

The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2'-deoxyuridine).

R D SULLIVAN, C W YOUNG, E MILLER, N GLATSTEIN, B CLARKSON, J H BURCHENAL.   

Abstract

Entities:  

Keywords:  NEOPLASMS/therapy; NUCLEOSIDES AND NUCLEOTIDES/therapy

Mesh：

Substances：

Year:  1960        PMID： 13835653

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  10 in total

1.  5-FLUOROURACIL TREATMENT OF LIVER METASTASES BY CONTINUOUS HEPATIC ARTERY INFUSION VIA COURNAND CATHETER: RESULTS AND SUITABILITY FOR INTENSIVE POSTSURGICAL ADJUVANT CHEMOTHERAPY.

Authors:  M J BRENNAN; R W TALLEY; E H DRAKE; V K VAITKEVICIUS; A K POZNANSKI; B E BRUSH
Journal:  Ann Surg       Date:  1963-09       Impact factor: 12.969

Review 2.  Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.

Authors:  R L Poorter; P J Bakker; C H Veenhof
Journal:  Pharm World Sci       Date:  1998-04

3.  The chemotherapy of large-bowel cancer. Present status and future prospects.

Authors:  J Horton; C B Hacker; T J Cunningham; R W Sponzo
Journal:  Am J Dig Dis       Date:  1974-11

4.  The clinical syndrome of 5-fluorouracil cardiotoxicity.

Authors:  J F Ensley; B Patel; R Kloner; J A Kish; J Wynne; M al-Sarraf
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

5.  Prolonged intra-aortic infusion therapy with anti-tumor agents for advanced cancer of the stomach, colon and rectum.

Authors:  K Yoshikawa; H Kitaoka
Journal:  Jpn J Surg       Date:  1971-12

6.  Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo.

Authors:  T Shirasaka; Y Shimamoto; H Ohshimo; H Saito; M Fukushima
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Antitumor activity of 3',5'-diesters of 5-fluoro-2'-deoxyuridine against murine leukemia L1210 cells.

Authors:  F Kanzawa; A Hoshi; K Kuretani; M Saneyoshi; T Kawaguchi
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.

Authors:  S Fujii; M Fukushima; Y Shimamoto; T Shirasaka
Journal:  Jpn J Cancer Res       Date:  1989-06

9.  Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma.

Authors:  Shuo-Han Zheng; Song-Ran Liu; Hai-Bo Wang; Ying-Hong Wei; He Li; Guan-Nan Wang; Zi-Lu Huang; Shi-Rong Ding; Chen Chen; Ya-Lan Tao; Xiao-Hui Li; Christophe Glorieux; Peng Huang; Yang-Feng Wu; Yun-Fei Xia
Journal:  JAMA Netw Open       Date:  2021-12-01

10.  Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats.

Authors:  S Fujii; Y Shimamoto; H Ohshimo; T Imaoka; M Motoyama; M Fukushima; T Shirasaka
Journal:  Jpn J Cancer Res       Date:  1989-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.